Targeting and Therapeutic Aspects

Yaping Liu,Yingying Huang,Guantao He,Chun Guo,Jinhua Dong,Linping Wu
DOI: https://doi.org/10.3390/ijms251810166
IF: 5.6
2024-09-23
International Journal of Molecular Sciences
Abstract:Lipid nanoparticles (LNPs) have emerged as leading non-viral carriers for messenger RNA (mRNA) delivery in clinical applications. Overcoming challenges in safe and effective mRNA delivery to target tissues and cells, along with controlling release from the delivery vehicle, remains pivotal in mRNA-based therapies. This review elucidates the structure of LNPs, the mechanism for mRNA delivery, and the targeted delivery of LNPs to various cells and tissues, including leukocytes, T-cells, dendritic cells, Kupffer cells, hepatic endothelial cells, and hepatic and extrahepatic tissues. Here, we discuss the applications of mRNA–LNP vaccines for the prevention of infectious diseases and for the treatment of cancer and various genetic diseases. Although challenges remain in terms of delivery efficiency, specific tissue targeting, toxicity, and storage stability, mRNA–LNP technology holds extensive potential for the treatment of diseases.
biochemistry & molecular biology,chemistry, multidisciplinary
What problem does this paper attempt to address?